1. In Vivo
  2. >>New Science

Funding The Future: Accelerating The Long Walk To Innovation

Good ideas must be paired with good people

 
• By Jo Shorthouse

In Vivo spoke with two company creators working in the biotech industry about their strategies for seeking new science and their funding philosophy when building the biotechs of tomorrow.  

accelerator people
Its the people involved in the deal that create company acceleration • Source: Shutterstock

Investment in ideas and new science takes research, and often faith to make innovation work. What may be a good idea on paper may not be scalable, or even answer an unmet need for patients. Entering the innovation arena before seed funding and venture capital are companies such as Deep Science Ventures and Oxford Science Enterprises, each taking its own approach to accelerating innovation.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Science

From Brain Waves to Better Outcomes: Inside Alto Neuroscience’s Biomarker Strategy

 
• By David Wild

Alto Neuroscience’s CEO, Amit Etkin, believes the company’s biomarker-based approach to psychiatric treatment is the way forward.

Building The Worm Atlas For I&I Breakthroughs

 
• By Ian Taylor

The next big thing in auto-immune therapies: worms. Or so a young California biotech believes. Holoclara is pioneering a new class of medicines derived from intestinal worms to revolutionize the treatment of autoimmune diseases, allergies, and more.

Podcast: Heranova CMO Advocates For Endometriosis Awareness: “Pain Is Not Normal”

 
• By Anabel Costa-Ferreira

Farideh Bischoff, chief medical officer of Heranova Lifesciences, discusses the urgent need for better diagnostic options and the latest innovations transforming care for endometriosis patients.

BPGbio: Fusing Patient-Driven Innovation With Causal AI

 
• By David Wild

Biotech BPGbio applies causal AI to generate insights from samples from what the CEO says is one of the world's largest biobanks. With several promising late-stage programs, its platform seems to be yielding fruit.

More from In Vivo

Rising Leaders 2025: Kevin Parker On Climbing Toward Breakthroughs In Biotech

 
• By Meredith Landry

Kevin Parker leads Cartography Biosciences in developing precision therapies for underserved cancer types, targeting proteins exclusive to tumor cells.

Deals In Depth: March 2025

 
• By Maureen Riordan

Eight $1bn+ alliances were penned in March, and five exceeded $2bn.

Biotech Leaders Ponder Trump’s Tariff Ramifications

 
• By Joseph Haas, Mary Jo Laffler, and Jessica Merrill

Several biotech execs said they don’t expect much impact from the Trump administration’s threatened tariffs but are reviewing business practices to prepare.